Real-world findings suggest GLP-1 drugs offer health benefits for young people with diabetes

New probe presented astatine the yearly gathering of the European Association for the Study of Diabetes (EASD) successful Milan, Italy, from Sept. 28–Oct. 2 examined the real-world usage of GLP-1 receptor agonist (GLP-1 RA) drugs successful children and young radical successful Germany, Austria and Luxembourg.